BullFrog AI Appoints Globally Renowned Biomedical AI Expert Dr. Thomas W. Chittenden as Chief Scientific Officer - Seite 2

A GIGA Society Fellow, Dr. Chittenden has been recognized for his exceptional intellectual contributions and achievements. His work extends beyond the corporate sector to his role as Chairman, Founding President, and Chief Scientist of the Complex Biological Systems Alliance, where he has been pivotal in advancing mathematical and theoretical systems biology through global collaborative research.

Dr. Chittenden's academic contributions are equally impressive, having served as a Senior Biostatistics and Computational Biology Consultant at Harvard Medical School, where he consulted for the HMS Research Community on Statistical Sciences and developed courses in Biostatistics and Computational Biology.

At BullFrog AI, Dr. Chittenden will lead the scientific strategy to further develop and implement cutting-edge AI-driven platforms for drug discovery and development. His vision for integrating AI and machine learning with biostatistics will be crucial in driving BullFrog AI's mission to accelerate the pace of drug development and bring innovative treatments to patients faster.

Dr. Chittenden commented, "I am thrilled to join BullFrog AI and to contribute to the Company's innovative approach to drug development. The opportunity to apply AI and machine learning technologies to revolutionize how we discover and develop new therapies is incredibly exciting. I look forward to working with the talented team at BullFrog AI to make significant strides in this dynamic field."

Dr. Chittenden's appointment as Chief Scientific Officer of BullFrog AI, effective February 26, 2024, marks a significant milestone for the Company as it continues to pioneer a new era of AI technology-enabled drug development. His leadership and expertise are expected to propel BullFrog AI to new heights in its mission to transform the landscape of drug discovery and development.

About BullFrog AI

BullFrog AI is a technology-enabled drug development company using Artificial Intelligence and machine learning to enable the successful development of pharmaceuticals and biologics. Through its collaborations with leading research institutions, BullFrog AI is at the forefront of AI-driven drug development using its proprietary bfLEAP artificial intelligence platform to create and analyze networks of biological, clinical, and real-world data spanning from early discovery to late-stage clinical trials. BullFrog AI is deploying bfLEAP for use at several critical stages of development with the intention of streamlining data analytics in therapeutics development, decreasing the overall development costs by decreasing failure rates for new therapeutics.